CDKN2B-AS1 and pulmonary arterial hypertension: Silencing of ANRIL with siRNA accelerated cell cycle progression and increased proliferation and migration of HPASMCs exposed to hypoxia [41], demonstrating that ANRIL played a crucial role in hypoxic HPASMCs with potentially far-reaching implications for the development of gene therapies and drugs for treating PAH.